Related Experiment Video
Updated: Jan 28, 2026

Spatial and Temporal Analysis of Active ERK in the C. elegans Germline
Published on: November 29, 2016
ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer
Mohamed I Saad1,2, Sultan Alhayyani1,2, Louise McLeod1,2
1Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Abstract:
Oncogenic KRAS mutations are major drivers of lung adenocarcinoma (LAC), yet the direct therapeutic targeting of KRAS has been problematic. Here, we reveal an obligate requirement by oncogenic KRAS for the ADAM17 protease in LAC In genetically engineered and xenograft (human cell line and patient-derived) KrasG12D-driven LAC models, the specific blockade of ADAM17, including with a non-toxic prodomain inhibitor, suppressed tumor burden by reducing cellular proliferation. The pro-tumorigenic activity of ADAM17 was dependent upon its threonine phosphorylation by p38 MAPK, along with the preferential shedding of the ADAM17 substrate, IL-6R, to release soluble IL-6R that drives IL-6 trans-signaling via the ERK1/2 MAPK pathway. The requirement for ADAM17 in KrasG12D-driven LAC was independent of bone marrow-derived immune cells. Furthermore, in KRAS mutant human LAC, there was a significant positive correlation between augmented phospho-ADAM17 levels, observed primarily in epithelial rather than immune cells, and activation of ERK and p38 MAPK pathways. Collectively, these findings identify ADAM17 as a druggable target for oncogenic KRAS-driven LAC and provide the rationale to employ ADAM17-based therapeutic strategies for targeting KRAS mutant cancers.
Insights
Targeting ADAM17 protease is a promising strategy for KRAS-mutant lung adenocarcinoma. Blocking ADAM17 reduces tumor growth by inhibiting proliferation and IL-6 trans-signaling pathways.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Oncogenic KRAS mutations are key drivers of lung adenocarcinoma (LAC).
- Directly targeting KRAS has proven challenging, necessitating alternative therapeutic strategies.
- ADAM17 protease has emerged as a potential mediator in KRAS-driven cancers.
Purpose of the Study:
- To investigate the role of ADAM17 protease in KRAS-driven lung adenocarcinoma.
- To determine if ADAM17 is a druggable target for treating KRAS-mutant LAC.
- To elucidate the molecular mechanisms by which ADAM17 promotes tumor growth.
Main Methods:
- Utilized genetically engineered and xenograft models of KRAS G12D-driven LAC.
- Employed a non-toxic prodomain inhibitor to block ADAM17 activity.
- Assessed tumor burden, cellular proliferation, and MAPK signaling pathways (p38, ERK).
- Investigated the role of ADAM17 substrate IL-6R and IL-6 trans-signaling.
- Analyzed phospho-ADAM17 levels in human KRAS-mutant LAC samples.
Main Results:
- Specific blockade of ADAM17 significantly suppressed tumor burden and reduced cellular proliferation in KRAS G12D-driven LAC models.
- ADAM17's pro-tumorigenic activity was dependent on p38 MAPK-mediated threonine phosphorylation.
- ADAM17 shedding of IL-6R released soluble IL-6R, driving IL-6 trans-signaling via ERK1/2 MAPK.
- The requirement for ADAM17 was independent of bone marrow-derived immune cells.
- Human KRAS-mutant LAC showed a positive correlation between phospho-ADAM17 levels and activated ERK/p38 MAPK pathways.
Conclusions:
- ADAM17 is an obligate requirement for oncogenic KRAS-driven lung adenocarcinoma.
- ADAM17 is a druggable target for therapeutic intervention in KRAS-mutant LAC.
- Targeting ADAM17 offers a promising strategy for treating KRAS-driven cancers.
More Related Videos
11:00Photostimulation by Femtosecond Laser Activates Extracellular-signal-regulated Kinase ERK Signaling or Mitochondrial Events in Target Cells
Published on: July 6, 2019
07:55Subcellular Fractionation for ERK Activation Upon Mitochondrial-derived Peptide Treatment
Published on: September 25, 2017
Related Concept Videos
MAPK Signaling Cascades
Hypothalamic-Pituitary Axis
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Perpendicular-Axis Theorem
Consider a circular disc of mass M and radius R lying along an x-y plane. The origin lies at the center of the disc, and the z-axis is perpendicular to the disc's plane. All three axes coincide at the disc's center. The moment of inertia of this...
Parallel-axis Theorem